Poolbeg has signed an option agreement with University College Dublin for MelioVac, a late preclinical-stage infectious disease vaccine for Burkholderia pseudomallei, the bacterium that causes the tropical disease melioidosis. The option provides a period of time for Poolbeg to complete its due dil
07 Dec 2021
Deal to acquire infectious disease vaccine candidates
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Deal to acquire infectious disease vaccine candidates
Poolbeg Pharma PLC (POLB:LON) | 10.2 0 0.0% | Mkt Cap: 51.0m
- Published:
07 Dec 2021 -
Author:
Robin Davison -
Pages:
2
Poolbeg has signed an option agreement with University College Dublin for MelioVac, a late preclinical-stage infectious disease vaccine for Burkholderia pseudomallei, the bacterium that causes the tropical disease melioidosis. The option provides a period of time for Poolbeg to complete its due dil